| Ημερομηνία | barcode | code | περιεχομενο | τιμή παραγωγός | χονδρική | λιανική |
|---|---|---|---|---|---|---|
| 05/2018 | 2802735601020 | 273560102 | XOMOLIX INJ.SOL 2,5MG/ML BTx 10 AMPS x 1 ML (σε γυάλινη φύσιγγα) (σε γυάλινη φύσιγγα) | 29.60 | 31.05 | 42.79 |
Droperidol is ssed to produce tranquilization and to reduce the incidence of nausea and vomiting in surgical and diagnostic procedures.
The exact mechanism of action is unknown, however, droperidol causes a CNS depression at subcortical levels of the brain, midbrain, and brainstem reticular formation. It may antagonize the actions of glutamic acid within the extrapyramidal system. It may also inhibit cathecolamine receptors and the reuptake of neurotransmiters and has strong central antidopaminergic action and weak central anticholinergic action. It can also produce ganglionic blockade and reduced affective response. The main actions seem to stem from its potent Dopamine(2) receptor antagonism with minor antagonistic effects on alpha-1 adrenergic receptors as well.
The intravenous LD<sub>50</sub> of droperidol is 20-43 mg/kg in mice; 30 mg/kg in rats; 25 mg/kg in dogs and 11-13 mg/kg in rabbits. The intramuscular LD<sub>50</sub> of droperidol is 195 mg/kg in mice, 104-110 mg/kg in rats; 97 mg/kg in rabbits and 200 mg/kg in guinea pigs. The manifestations of droperidol overdosage are an extension of its pharmacologic actions.
Completely absorbed following intramuscular administration.
Biphasic distribution. The rapid distribution phase is 1.4 &plusmn; 0.5 minutes and the slower distribution phase is 14.3 &plusmn; 6.5 minutes. Elimination half-life in adults is 134 &plusmn; 13 minutes and may be increased in geriatric patients. In children, it is 101.5 &plusmn; 26.4 minutes.